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1  | INTRODUC TION
The central melanocortin system is known to play a pivotal role in 
the regulation of energy metabolism and food intake. Mutations in 
the central melanocortin‐4 receptor (MC4R) are found in approx‐
imately one out of every 1500 individuals and are associated with 
up to 6% of cases of severe early‐onset monogenic obesity.1,2 MC4R 
is a class A (rhodopsin‐like), seven‐transmembrane G‐protein‐cou‐
pled‐receptor (GPCR) that is shown to signal primarily through the 
Gαs > adenylyl cyclase > cAMP pathway. This signalling pathway in 
MC4R neurones is known to be required for control of thermogene‐
sis, energy balance and glucose metabolism.3 A classification system 
was previously proposed4 sorting obesity‐associated MC4R muta‐
tions into functional classes described as loss‐of‐function mutations 
caused by defective expression (class I mutants), disrupted traffick‐
ing of the receptor (class II mutants), decreased binding affinity (class 
III mutants) or defective coupling to Gαs (class IV mutants).
5‐9 Yet, 
up to 26% of obesity‐associated MC4R mutations10 exhibit normal 
receptor activity with respect to these four criteria.11,12 Although 
it is possible that these “class V” mutations are non‐pathogenic, re‐
cent studies have suggested that MC4R signalling is quite complex. 
The MC4R signalling complex appears to involve a number of ac‐
cessory proteins.13‐19 Furthermore, the MC4R appears to signal dif‐
ferently in different neuronal cell types, coupling to a KATP channel 
to hyperpolarise cells in the brainstem,20 whereas it couples to an 
inwardly rectifying potassium channel, Kir7.1, independent of G‐
proteins, mediating α‐melanocyte‐stimulating hormone (MSH)‐in‐
duced membrane depolarisation in the paraventricular nucleus.15,21 
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Abstract
Mutations in the melanocortin‐4 receptor (MC4R) are the most common cause of 
early syndromic obesity known. Most of these mutations result in a loss of protein 
expression, α‐melanocyte‐stimulating hormone binding, receptor trafficking or cou‐
pling to the stimulatory G‐protein, Gαs. However, approximately 26% of the obesity‐
associated mutations characterised to date exhibit none of these pharmacological 
defects. In the present study, we investigated seven of these apparently normal 
mutant MC4R in more detail and found that the majority (five of the seven) exhibit 
marked defects including defective binding of another endogenous melanocortin li‐
gand, defective glycosylation, and defective recruitment of β‐arrestin. These data 
provide support for two hypotheses: (i) that the majority of these rare, obesity‐as‐
sociated mutations are likely defective and causative of obesity and (ii) that β‐arrestin 
recruitment is a valuable marker of normal MC4R function. Recent work has dem‐
onstrated a statistical correlation between the efficacy of β‐arrestin recruitment to 
the MC4R and body mass index; however, the data reported here demonstrate both 
decreased and increased β‐arrestin signalling in obesity‐associated MC4R mutations.
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The melanocortin‐2 receptor‐associated protein 2 (MRAP2) has also 
been shown to suppress the constitutive activity at the receptor and 
regulate sensitivity to α‐MSH. Deletion of MRAP2 in both zebrafish 
and mice has resulted in increased adiposity.13,14 Four potentially 
pathogenic variants of MRAP2 were also identified in early‐onset 
obese humans.13 Upon ligand activation, GPCRs are known to re‐
cruit β‐arrestin and were considered to only lead to receptor desen‐
sitisation, internalisation and either recycling of the receptor back to 
the membrane or downstream degradation.22 However, recent stud‐
ies have shown that recruitment of β‐arrestin can couple the recep‐
tor to intracellular, G‐protein independent signalling cascades.23,24 
One study has reported highly variable recruitment of β‐arrestin by 
naturally occurring MC4R variants identified in the UK Biobank, and 
demonstrated a statistical correlation between the efficacy of β‐ar‐
restin recruitment to the MC4R and body mass index (BMI).25
Beyond simply elucidating the signalling mechanism(s) of a re‐
ceptor critical to energy homeostasis, further investigation of this 
receptor is needed to advance attempts to develop small molecule 
therapeutics at this receptor, given the finding of a target‐mediated 
pressor response.26‐28 A more detailed pharmacological model of 
receptor signalling, for example, may allow for the development of 
biased agonists that stimulate weight loss but not the pressor re‐
sponse. To better understand essential functional features of the 
MC4R that have not yet been elucidated, we aimed to identify 
potential biochemical and/or pharmacological defects in class V 
obesity‐associated MC4R mutations reported to have normal cell 
surface expression, ligand binding and coupling to Gαs.
2  | MATERIAL S AND METHODS
2.1 | Selection of MC4R variants
The seven MC4R variants chosen for study, aspartate‐37‐va‐
line (D37V),5 proline‐48‐serine (P48S),5 valine‐50‐methionine 
(V50M),5,29 histidine‐76‐arginine (H76R),2,11 isoleucine‐170‐valine 
(I170V),5,29 asparagine‐274‐serine (N274S)5 and arginine‐305‐serine 
(R305S)2,11 were identified from the published literature using spe‐
cific criteria: (i) implicated in the development of obesity in humans; 
(ii) resulting in a full‐length protein upon translation; and (iii) no 
known molecular defects in terms of G‐protein coupling, cell surface 
expression and ligand binding affinity.
2.2 | Cells, plasmids, mutagenesis and transfection
All experiments were performed in Chinese hamster ovary (CHO‐
K1) cells (ATCC CC61) maintained in a 37°C tissue culture incubator 
with 5% CO2. Growth media consisted of Gibco (Gaithersburg, MD, 
USA) Dulbecco’s modified Eagle’s medium/F‐12 with 4‐(2‐hydroxy‐
ethyl)‐1‐piperazineethanesulphonic acid, 10% foetal bovine serum 
and 1% antibiotic/antimycotic. Cells were no longer used for experi‐
mental purposes past passage number 15. The human MC4R plas‐
mid was obtained from cDNA.org (catalogue no. MCR040TN00) and 
contained an N‐terminal 3‐human influenza hemagglutinin (3HA) 
tag cloned in pcDNA3.1+ (Invitrogen, Carlsbad, CA, USA) with the 
MC4R sequence cloned at the KpnI and XhoI restriction sites. This 
plasmid was used as the template to create mutant receptor vectors 
via site‐directed mutagenesis. pSF‐CMV‐NEO‐COOH‐3xFLAG plas‐
mid was obtained from Sigma‐Aldrich (St Louis, MO, USA; catalogue 
no. OGS629‐5UG). The sequence for wild‐type (WT) human MRAP2 
was cloned into SacI and XhoI restriction sites using a polymerase 
chain reaction (PCR) and Quick Ligase (New England Biolabs, Beverly, 
MA, USA; catalogue no. M2200). All transfections were performed 
transiently with FuGene HD (Promega, Madison, WI, USA; catalogue 
no. E2312) using a reverse transfection protocol. A cAMP‐sensitive 
luciferase plasmid (pGL4.29), used for cAMP accumulation assays, 
was purchased from Promega (catalogue no. E8471). Plasmids for 
the NanoBit assay (Promega N2014) were provided in the starter 
kit (Promega; catalogue no. N2014). Human β‐arrestin 2 coding se‐
quence was cloned into C‐terminal SmallBit plasmid at the EcoRI 
and SacI restriction sites. Cloning of mutant human MC4R recep‐
tors into N‐terminal LargeBit was performed by amplifying mu‐
tant MC4R sequence via PCR using corresponding oligonucleotide 
primers, followed by Dpn1 digestion, restriction enzyme digestion, 
dephosphorylation of open vector, quick ligation and Escherichia coli 
transformation.
2.3 | Antibodies
Western blotting was performed using the antibodies: HA‐tag (6E2) 
mouse (Cell Signaling Technology, Beverly, MA, USA; catalogue no. 
2999); HA‐tag (6E2) mouse mAb (horseradish peroxidase [HRP] 
conjugate) (Cell Signaling Technology; catalogue no. 2367; diluted 
1:5000); anti‐FLAG M2 mouse (Sigma‐Aldrich; catalogue no. F3165); 
anti‐FLAG M2‐peroxidase mouse (Sigma‐Aldrich; catalogue no. 
A8592; diluted 1:10 000); GAPDH (D16H11) XP rabbit (HRP con‐
jugate) (Cell Signaling Technology; catalogue no. 8884S; diluted 
1:5000); β‐actin (8H10D10) mouse mAb (Cell Signaling Technology; 
catalogue no. 3700S; diluted 1:5000); and anti‐mouse immunoglob‐
ulin G, HRP‐linked (Cell Signaling Technology; catalogue no. 7076S; 
diluted 1:10 000).
2.4 | In vitro mutagenesis of MC4R
Mutant MC4R receptors were created via site‐directed mutagenesis 
using QuikChange II XL (Agilent Technologies Inc., Santa Clara, CA, 
USA; catalogue no. 200521) in accordance with the manufacturer’s 
instructions. Following PCR amplification, plasmids were trans‐
formed into provided ultracompetent XL‐10 gold E. coli cells and al‐
lowed to propagate in a 37°C rocking incubator for 1 hour before 
streaking on a Luria broth agar plate containing ampicillin. These 
plates were incubated overnight at 37°C and single colonies were 
picked and inoculated in liquid Luria broth media containing ampicil‐
lin and allowed to propagate overnight. DNA was then isolated from 
bacterial cultures using a QiaPrep Miniprep kit (Qiagen, Valencia, 
CA, USA; catalogue no. 27 106). Mutagenesis was then confirmed 
via Sanger sequencing provided by the DNA sequencing core at the 
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University of Michigan (Ann Arbor, MI, USA) prior to use in experi‐
mental assays.
2.5 | MSH‐induced Gαs coupling and 
accumulation of intracellular cAMP
CHO cells were plated and transfected in white, flat‐bottomed 
96‐well plates (Corning Inc., Corning, NY, USA; catalogue no. 
CLS3917) with a cAMP‐sensitive luciferase plasmid and corre‐
sponding empty vector, variant receptor, and/or MRAP2 plasmids 
using methods as described above. Transfection was performed 
with 0.2 µg of DNA per well (0.1 µg of luciferase and 0.1 µg of 
experimental plasmids). Variant receptor ± MRAP2 (or empty vec‐
tor) was transfected at a ration of 1:6. Each condition was plated in 
triplicate. Forty‐eight hours after transfection, growth media was 
removed and 50 µL of Opti‐MEM was added to each well (Gibco; 
catalgoue no. 11 058 021). Then, 50 µL of a serial dilution (starting 
concentration of 10 pmol L‐1, ending concentration of 1 µmol L–1) 
of α‐MSH (Bachem AG, Bubendorf, Switzerland; catalogue no. 
H‐1075), β‐MSH (Phoenix Pharmaceuticals Inc., Belmont, CA, 
USA; catalogue no 043‐12) or des‐acetyl‐α‐MSH (Bachem AG; cat‐
alogue no. H‐4390) was added to corresponding wells, as well as 
a forskolin (Sigma‐Aldrich; catalogue no. F6886) control for each 
transfection condition. Cells were allowed to incubate at 37°C for 
4 hours. Following incubation, all liquid was removed from the 
cells and 50 µL of room temperature Dulbecco’s phosphate‐buff‐
ered saline (DPBS) (Gibco; catalogue no. 14 040 133) was added to 
the cells followed by 50 µL of room temperature ONE‐Glo EX lu‐
ciferase substrate (Promega; catalogue no. E8120). The plate was 
covered with foil and allowed to incubate at room temperature 
for 10 minutes on an orbital rocker before reading luminescence 
on an Enspire microplate reader (PerkinElmer, Waltham, MA, 
USA). Averages of triplicate conditions were calculated using excel 
(Microsoft Corp. Redmond, WA, USA) and expressed as a per‐
centage of the WT maximum response. Concentration‐response 
curves were generated by pooling data from three independent 
experiments. Maximal responses (Emax) and EC50 values were cal‐
culated using prism (GraphPad Software Inc., San Diego, CA, USA). 
A one‐way ANOVA statistical test was applied to pEC50 and Emax 
values to determine significance (P < .05), with a Bonferroni post‐
hoc test for multiple comparisons.
2.6 | Co‐immunoprecipitation
CHO cells were transiently transfected in 6‐cm poly‐d‐lysine 
coated plates using FuGene HD transfection reagent (Promega) 
and allowed to incubate at 37°C for 48 hours. DNA concentrations 
were as follows: 5 µg of DNA was transfected per plate. Receptor 
variant ± MRAP2 or empty vector was transfected at a ratio of 
1:3 ratio. Cells were gently rinsed twice with room temperature 
DPBS followed by cross‐linking for 15 minutes at room tempera‐
ture with 1mmol L‐1 dithiobis(succinimidyl propionate) (Thermo 
Scientific, Waltham, MA, USA; catalogue no. PG82081). Reaction 
was stopped using 10 mmol L‐1 Tris(hydroxymethyl)aminometh‐
ane‐hydrochloride solution for 15 minutes at room temperature. 
Cell lysates were then harvested by adding radioimmunoprecipita‐
tion assay buffer (RIPA buffer) to each plate followed by scraping 
and allowing plate to incubate on rocker at 4°C for 30 minutes. 
The contents of each plate were then added to a clean Eppendorf 
tube and centrifuged at 9600g for 10 minutes. Supernatants were 
collected in fresh Eppendorf tubes followed by a Pierce bicin‐
choninic acid protein quantification assay. Next, 100 µg of lysate 
in a total volume of 500 µL was incubated overnight with 1 µg of 
antibody on a rotator at 4°C. The next day, protein G magnetic 
beads (Thermo Scientific; catalogue no. 88 848) were rinsed and 
resuspended in RIPA buffer. Then, 30 µL of beads were added to 
each tube and allowed to incubate on rocker at 4°C for 1 hour. 
Using a magnetic rack, beads were washed three times with RIPA 
buffer and eluted in 50 µL of 3× lithium dodecyl sulphate buffer 
(Thermo Scientific; catalogue no. B0007) with 200 mmol L‐1 dithi‐
othreitol. Samples were allowed to rest at room temperature for 
15 minutes before loading 20 µL on sodium dodecyl sulfate‐poly‐
acrylamide gel electrophoresis (SDS‐PAGE) gel. Blots were imaged 
on chemidoc (Bio‐Rad, Hercules, CA, USA).
2.7 | Endoglycosidase treatment for confirmation of 
MC4R glycosylation
CHO cells were plated and transfected in 10‐cm poly‐d‐lysine 
coated plates in the same manner as previously detailed and allowed 
to incubate at 37°C for 48 hours. Cells were transfected with 8 µg 
of receptor variant DNA per plate. Cell lysates were then harvested 
as described above. To assess the glycosylation pattern, Endo H 
(New England BioLabs; catalogue no. P0702S) and PNGase F (New 
England BioLabs; catalogue no. P0704S) were used in accordance 
with the manufacturer’s instructions. Samples were then run on an 
SDS‐PAGE gel and analysed via western blot using chemidoc imager 
and image lab (Bio‐Rad).
2.8 | Western blots
Ten to 15 µg of protein from prepared cell lysates was loaded 
into corresponding lanes on Bolt 4%‐12% Bis‐Tris Plus precast po‐
lyacrylamide gels (Invitrogen; catalogue no. NW04122) at 200V 
for 30‐40 minutes using Bolt Mops running buffer (Invitrogen; 
catalogue no. B000102). Bolt antioxidant (Invitrogen; catalogue 
no. BT0005) was added to the first chamber of the mini gel tank 
(Invitrogen; catalogue no. A25977). Transfer to Immobilon poly‐
vinylidene fluoride membrane (Millipore, Burlington, MA, USA; 
catalogue no. IPVH00010) was performed using a transblot turbo 
system (Bio‐Rad; catalogue no. 1704150EDU). Membranes were 
blocked with 5% non‐fat dry milk in phosphate‐buffered saline with 
1% Tween‐20 overnight at 4°C. Blots were then washed a minimum 
of three times for 15 minutes each before imaging using SuperSignal 
West Dura Extended Detection Substrate (Thermo Scientific; cata‐
logue no. 34 075) using chemidoc touch (Bio‐Rad).
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2.9 | MSH‐induced β‐arrestin recruitment
CHO cells were transiently transfected in white, flat‐bottomed 96‐
well plates with WT or mutant‐MC4R‐LgBit and SmBit‐β‐arrestin 
plasmids (0.2 µg of DNA/well at a ratio of 1:1) using FuGene HD 
transfection reagent and allowed to incubate at 37°C for 48 hours. 
On the day of experiment, all media was removed from cells and re‐
placed with 25 µL of room temperature DPBS (Gibco) and allowed 
to equilibrate at room temperature for 10 minutes. Next, 25 µL 
of room temperature NanoGlo Live Cell Substrate was added to 
each well, and then the plate was wrapped in foil and gently mixed 
on an orbital shaker for 15 seconds. Background luminescent sig‐
nal was measured for 5 minutes using the PerkinElmer Enspire 
microplate reader. Then, 50 µL of a serial dilution (starting con‐
centration of 10 pmol L‐1, ending concentration of 10 µmol L‐1) of 
α‐MSH or β‐MSH was added to corresponding wells, covered with 
foil and allowed to incubate at room temperature for 10 minutes 
before measuring luminescent signal on microplate reader. The 
optimal time point was chosen as 10 minutes because the signal 
was observed to peak at this time. Each condition was measured 
from triplicate wells in each experiment, and each experiment was 
performed at least three times independently. For data analysis, 
raw values for background measurement were averaged and used 
to normalise the MSH response for each corresponding well. The 
normalised values for the stimulated wells were then averaged. 
Concentration‐response curves were generated by pooling data 
from three independent experiments. The concentration‐response 
curves for these data were generated in prism and analysed to de‐
termine Emax and EC50. A one‐way ANOVA statistical test was ap‐
plied to pEC50 and Emax values to determine significance (P < .05), 
with a Bonferroni post‐hoc test for multiple comparisons.
3  | RESULTS
3.1 | Gαs coupling of MC4R variants in response to 
α‐ and β‐MSH
In the present study, seven different human obesity‐associated 
class V variants of the MC4R (Figure 1) were characterised in 
CHO‐K1 cells. These seven mutations were previously identified in 
obese patients and assessed for G‐protein coupling, binding affin‐
ity and cell surface expression,30 and categorised as Class V vari‐
ants, based on normal cell surface expression, ligand binding and 
coupling to Gαs.
30
To characterise the coupling of the mutant receptors to Gαs 
in response to α‐MSH or β‐MSH, we used a cAMP‐responsive lu‐
ciferase to measure the accumulation of cAMP upon activation 
by either ligand. In response to α‐MSH (Figure 2A‐F), one variant 
F I G U R E  1   A, Schematic representation of melanocortin‐4 receptor (MC4R). Amino acids are indicated as a single‐letter code within 
circles. Those affected by mutations and assessed within the present study are represented by yellow diamonds. The corresponding amino 
acid change is noted for each variant. N‐linked glycosylation sites are represented by green squares. The seven‐transmembrane domains are 
indicated by roman numerals. EL, extracellular loop; IL, intracellular loop. Schematic generated using Protter online interactive software.  
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(V50M) exhibited a significant increase in EC50, whereas two vari‐
ants (V50M and H76R) exhibited a significant decrease in Emax. In 
response to β‐MSH (Figure 2G‐L), one variant exhibited a signifi‐
cant increase in EC50 (H76R), whereas I170V exhibited an increase 
in maximum response. These data suggest that five of these re‐
ceptor variants exhibit fully normal responses to both α‐MSH and 
β‐MSH (D37V, P48S, I170V, N274S and R305S). H76R also exhib‐
ited significant constitutive activity in our assay (see supporting 
information, Figure S1).
A recent study found that des‐acetyl‐α‐MSH was the predom‐
inant form of MSH in the adult human brain.31 Previous studies 
in which α‐MSH was employed to perform molecular assays used 
acetylated α‐MSH, as in the present study. To determine whether or 
not the acetylation status of MSH might have affected these results, 
we ran the cAMP accumulation assay and compared findings using 
WT and two variant receptors (D37V and V50M) (see supporting 
information, Figure S2). No significant differences were found when 
comparing EC50 values in response to α‐MSH vs des‐acetyl‐α‐MSH 
at the WT and variant receptors tested.
F I G U R E  2   Accumulation of intracellular cAMP in Chinese hamster ovary (CHO‐K1) cells transiently transfected with wild‐type (WT) 
and mutant melanocortin‐4 receptor (MC4R). Transfected cells were treated with α‐MSH (A‐C) or β‐MSH (D‐F) and intracellular cAMP was 
measured using a luciferase‐based assay described in the Materials and methods. All experiments were run in triplicate and performed at 
least three times. Concentration‐response curves represent the means of three independent experiments. Results are expressed as the 
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3.2 | MRAP2 interacts with and is able to suppress 
constitutive activity of all variants
In the present study, we aimed to test whether class V obesity‐
associated MC4R receptors associated with obesity have defects 
in signalling that are not detected by a conventional Gαs coupling 
assay. MC4R exhibits a significant degree of constitutive activ‐
ity, and MRAP2 has been shown to inhibit this activity, as well as 
increase responsiveness to α‐MSH.14 Thus, mutations enhancing 
the suppression of MC4R activity by MRAP2, or compromising 
MRAP2 effects on responsiveness to ligand, might be expected to 
reduce MC4R activity, which could be expected to cause obesity. 
To characterise the protein‐protein interaction between MRAP2 
and MC4R variants, we first performed co‐immunoprecipitation 
from cell lysates collected from CHO‐K1 cells that were transiently 
transfected with WT or mutant MC4R (N‐terminal 3HA epitope 
tag; anticipated MW: 37 kDa) with or without co‐transfection of 
MRAP2 (C‐terminal 3xFLAG epitope tag; anticipated MW: 28 kDa). 
According to previous studies, MRAP2 pulls down as a doublet 
representing unglycosylated and glycosylated forms of the protein. 
The band observed above this doublet has been suggested to be 
a more highly glycosylated form of MRAP2, although this is yet to 
be confirmed. We found that each MC4R variant was able to pull 
down MRAP2 in a manner comparable to WT MC4R (Figure 3A, 
bottom row).
To assess the ability of MRAP2 to suppress the constitutive 
activity of each variant, we performed a luciferase‐based assay 
measuring the basal levels of cAMP in CHO‐K1 cells transiently 
transfected with WT or mutant MC4R with or without MRAP2 
(Figure 3B). We further tested whether MRAP2 had any effect on 
the WT or mutant receptor’s response to α‐MSH or β‐MSH and 
found that there no significant differences (see supporting infor‐
mation, Figure S3). Taken together, these results show that there 
were no defects in these class V variants with respect to suppres‐
sion of constitutive activity, or alteration in ligand responsiveness 
by MRAP2.
3.3 | V50M variant exhibits a putative defect in N‐
linked glycosylation
We next examined the glycosylation state of each variant MC4R pro‐
tein. Using cell lysates from transiently transfected CHO‐K1 cells, 
we performed western blots to assess the size and banding pattern 
of the WT and mutant MC4Rs. Interestingly, MC4R V50M exhibited 
an altered migration pattern compared to WT and this pattern was 
similar to a variant of MC4R (N26Q) in which one of four N‐linked 
glycosylation sites had been mutated (Figure 4A). We used the Endo 
H and PNGase F endoglycosidases to confirm the glycosylation of 
WT MC4R and also to confirm the defect in receptor glycosylation by 
the V50M mutation. PNGase F is able to cleave all glycans, core and 
complex, from a protein, whereas the Endo H enzyme is only able to 
cleave core glycans. Therefore, if a protein has complex glycosylation, 
it will be resistant to Endo H but not PNGase F, and no band shift will 
be observed. The results from these experiments (Figure 4B) sug‐
gest that WT MC4R undergoes core but not complex glycosylation. 
V50M again exhibits an altered migration pattern compared to WT 
MC4R and similar to the N26Q mutant. Both of these mutations are 
shown to be glycosylated, although not to the same extent as WT; 
thus, the absence of a single glycosylation event in the V50M mutant 
is consistent with the data.
F I G U R E  3   A, Melanocortin‐2 receptor‐associated protein 2 (MRAP2) (C‐terminal 3xFLAG tag; anticipated MW: 28 kDa,) protein 
interaction with WT and mutant melanocortin‐4 receptor (MC4R) (N‐terminal 3HA tag; anticipated MW: 37 kDa) was assessed using co‐
immunoprecipitation and western blot techniques described in the Materials and methods. Single blots are shown representative of three 
individual experiments per set of variants. B, Effect of MRAP2 interaction on constitutive activity of wild‐type (WT) and mutant MC4Rs was 
assessed using a luciferase‐based assay as described in the Materials and methods. Bar graphs represent the level of cAMP accumulation 
when Chinese hamster ovary (CHO‐K1) cells were transiently transfected with MC4R ± MRAP2. Results are expressed as the mean ± SEM 
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3.4 | Five of seven variants tested have altered β‐
arrestin recruitment in response to α‐ or β‐MSH
Upon activation, GPCRs are known to recruit β‐arrestin, which leads 
to downstream intracellular events such as receptor internalisation, 
or to novel pathways of intracellular signalling. To assess the recruit‐
ment of β‐arrestin to WT and mutant MC4Rs in response to α‐MSH 
or β‐MSH, we utilised the NanoBit luciferase‐based complementation 
assay (Promega). WT or mutant receptors were fused to the “large bit” 
of a Nano‐luciferase enzyme at the C‐terminal end, whereas β‐arrestin 
was fused to the “small bit” at the N‐terminal end. These constructs 
were then transiently co‐transfected into CHO‐K1 cells and treated 
with α‐MSH or β‐MSH. To determine whether the fusion of the “large 
bit” affects the “normal” signalling of the receptor, we compared the 
3HA‐WT‐MC4R construct with the LgBit‐fused receptor at coupling to 
Gs via the cAMP accumulation assay described previously. We found 
that the fusion of the “large bit” did suppress the constitutive activity 
of the receptor and altered the EC50 values compared to the un‐fused 
receptor but did not affect its ability to respond normally to ligand 
(see supporting information, Figure S4A‐D). To confirm that MC4R‐ar‐
restin interaction was specific, we co‐transfected CHO‐K1 cells with 
HaloTag protein fused to the “small bit” (Promega), and MC4R wt and 
mutant constructs, fused to large bit. The HaloTag protein is expressed 
throughout the cell and should not interact with “large bit” fused pro‐
teins in a concentration‐dependent manner. We found this to be true 
in our experimental set‐up (see supporting information, Figure S4E‐H), 
therefore suggesting that the β‐arrestin recruitment, as well as any ob‐
served defects, are specific to ligand‐induced MC4R activation. Five 
of the seven variants tested had either reduced or excessive β‐arrestin 
recruitment in response to α‐MSH or β‐MSH (Figure 5 and Table 1). 
P48S, V50M, H76R, I170V and N274S had either or both altered EC50 
or Emax for β‐arrestin recruitment compared to WT in response to 
α‐MSH, whereas P48S, V50M and H76R had either or both altered 
EC50 or Emax compared to WT in response to β‐MSH. Data compar‐
ing EC50 values for coupling to Gαs with EC50 values for β‐arrestin 
recruitment may be seen in Table 1. These data suggest that the inter‐
action between MC4R and β‐arrestin is an important pathway in the 
regulation of MC4R signalling and its normal function with respect to 
maintaining body weight.
4  | DISCUSSION
The melanocortin‐4 receptor is one of the most well‐validated drug 
targets for the treatment of obesity. However, many peptide and 
small molecule drugs targeting MC4R have failed in clinical trials 
as a result of a target‐mediated increase in blood pressure.26‐28 The 
growing interest in biased signalling in GPCR drug discovery high‐
lights the urgency to explore novel signalling pathways when con‐
sidering target‐specific therapeutics.32‐36 Interestingly, a subset of 
MC4R mutations in humans is associated with the development of 
obesity, yet these have been reported to couple normally to Gαs. 
Upon MC4R agonist binding, Gαs signalling leads to activation of 
adenylyl cyclase and elevation of intracellular cAMP that may go on 
to activate cAMP‐responsive element‐binding protein.37 Some data 
suggests that Gαs signalling is critical for MC4R signalling and regu‐
lation of body weight because deletion of the GNAS gene encoding 
Gαs in MC4R neurones recapitulates the entirety of the obesity syn‐
drome following MC4R deletion.3,38 However, deletion of cAMP‐re‐
sponsive element‐binding protein in the paraventricular nucleus has 
no influence on the ability of MC4R agonist, MTII, to inhibit food in‐
take.39 These data, along with the complexity of MC4R signalling and 
multiple MC4R accessory proteins, further highlight the likelihood 
that multiple signalling pathways are important for the function of 
MC4R and its regulation of food intake and body weight. Being able 
to identify receptor variants with specific pathway defects would 
allow further insight into the complexity of MC4R‐mediated regula‐
tion of energy homeostasis and potentially aid in the development 
of therapeutics for the treatment of obesity without the side effect 
profile. Activation of extracellular signal‐regulated protein kinases 1 
F I G U R E  4   A, Cell lysates from Chinese hamster ovary (CHO‐K1) cells transiently transfected with wild‐type (WT) or mutant 
melanocortin‐4 receptor (MC4R) were collected and analysed for glycosylation pattern, seen as a shift in migration compared to WT. N26Q 
is a mutation of one of the known glycosylation sites of MC4R. B, Confirmation of glycosylation was performed using EndoH and PNGase F 
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F I G U R E  5   Recruitment of β‐arrestin in Chinese hamster ovary (CHO‐K1) cells transiently transfected with wild‐type (WT) and mutant 
melanocortin‐4 receptors (MC4Rs). Transfected cells were treated with α‐MSH (A‐C) or β‐MSH (D‐F) and β‐arrestin recruitment was 
measured using a luciferase‐based, enzyme complementation assay described in the Materials and methods. All experiments were run 
in triplicate and performed at least three times. Concentration‐response curves represent the means of three independent experiments. 

















































































































































































































































TA B L E  1   Log EC50 values of WT and mutant MC4R for GαS coupling and for recruitment of β‐arrestin. Data are from Figure 2 and 5
 
LogEC50 (mean ± SEM)
α‐MSH β‐MSH
GαS coupling (cAMP) β‐arrestin recruitment GαS coupling (cAMP) β‐arrestin recruitment
Wild‐type −9.45	±	0.10 −7.08	±	0.06 −9.06	±	0.30 −6.62	±	0.07
D37V −9.23	±	0.12 −7.01	±	0.12 −8.93	±	0.18 −6.49	±	0.08
P48S −9.07	±	0.12 −6.90	±	0.10 −8.87	±	0.27 −6.38	±	0.07
V50M −8.90	±	0.15 −7.60	±	0.35 −8.98	±	0.18 −7.42	±	0.26
H76R −9.00	±	0.19 −7.42	±	0.12 −7.81	±	0.38 −6.51	±	0.29
I170V −9.04	±	0.10 −6.93	±	0.18 −8.67	±	0.21 −6.64	±	0.26
N274S −9.04	±	0.11 −7.44	±	0.13 −8.70	±	0.29 −6.56	±	0.12
R305S −9.16	±	0.90 −7.19	±	0.43 −9.08	±	0.14 −6.75	±	0.10
Abbreviation: MSH, melanocyte‐stimulating hormone.
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and 2 is known to occur downstream of both G‐protein and β‐arres‐
tin signalling; thus, in a previous study, only a small fraction of class 
V mutants tested (five of 25) exhibited reduced phosphorylation 
of extracellular signal‐regulated protein kinases 1 and 2 following 
[Nle4,D‐Phe7]‐α‐MSH treatment out of 293 cells transfected with 
MC4R.40
In the present study, we functionally characterised seven class 
V variants of the MC4R and showed that there are indeed other G‐
protein‐dependent and G‐protein‐independent signalling pathways 
defective in most of the receptor mutants in this class (Table 2). 
Mutations in the region of the pro‐opiomelanocortin gene that en‐
codes β‐MSH have been shown to result in severe obesity in humans, 
demonstrating that it is also an important ligand in the central con‐
trol of energy homeostasis.40‐42 In the present study, we show that 
some class V mutants, such as H76R, exhibit reduced responsiveness 
to β‐MSH in both Gαs coupling and β‐arrestin recruitment assays. 
This further supports the hypothesis that loss of β‐MSH activity at 
MC4R is important for the normal regulation of energy homeostasis.
The most surprising finding was that a majority of the obesity 
variants characterised in the present study exhibited alteration in 
β‐arrestin recruitment. During the preparation of this manuscript, a 
study of a large collection (n = 49) of naturally occurring variants 
of the MC4R demonstrated a statistical correlation between the ef‐
ficacy of β‐arrestin recruitment to the MC4R and BMI, which is a 
correlation not found with coupling to Gαs.
25 Importantly, many of 
these variants analysed in the present study are not associated with 
morbid syndromic obesity. By contrast, the majority of obesity‐asso‐
ciated mutations result in defective cAMP signalling. Furthermore, 
although four of seven obesity‐associated mutations characterised 
here exhibited decreased β‐arrestin recruitment, 1 exhibited an in‐
crease in maximal β‐arrestin recruitment (P48S), whereas a second 
indicated a trend towards increased β‐arrestin recruitment (D37V). 
In these cases, it is possible that the mutations lead to obesity by 
increasing internalisation, rather than producing defective β‐arrestin 
signal transduction.
Thus, distinct from the argument in Lotta et al,25 our interpre‐
tation of the data suggests that β‐arrestin recruitment is a marker 
of normal MC4R function, although the data do not yet support a 
role for β‐arrestin signalling in BMI. Lotta et al25 did not report the 
EC50 values for β‐arrestin recruitment. However, it is important to 
note from the data reported in the present study that, although EC50 
values are highly assay‐dependent, we nonetheless observed that 
the native ligand α‐MSH is more than two hundred fold more potent 
in Gαs‐mediated signalling than recruitment of β‐arrestin, with fu‐
sion of the large bit tag (see also supporting information, Figure S4) 
only accounting for a 10‐fold shift in EC50 (EC50 for α‐MSH‐induced 
coupling to Gαs = 3.4 × 10
−10; EC50 for α‐MSH‐induced β‐arrestin 
recruitment = 8 × 10−8). Further experimentation is necessary to 
identify the molecular and physiological consequences of β‐arrestin 
recruitment to the MC4R because MC4R signalling through β‐arres‐
tin has not yet been demonstrated.
Previous studies have shown that MC4R exhibits constitutive ac‐
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A cluster in the N‐terminal domain of the receptor was identified after 
characterisation of several naturally occurring, obesity‐associated mu‐
tations of the MC4R. None of the receptor variants that were included 
in the present study are located in this cluster; however, constitutive 
activity has also been shown to be regulated by interaction with the 
accessory protein, MRAP2.14,44 In the present study, we show that co‐
expression of the MRAP2 in vitro is still able to suppress the constitu‐
tive activity of the seven class V receptors tested here. Expansion of 
the variants tested could possibly lead to the identification of variants 
with defects in MRAP2 interaction. The possibility of MC4R coupling 
to other G‐proteins is still debated. It is noted that some studies have 
claimed that MC4R interacts with the inhibitory G‐protein, Gi/o, which 
leads to a decrease in cAMP production.45 Other studies suggest that 
MC4R couples to Gq/11 and mediates the mobilisation of intracellular 
free calcium.43,46 However, we did not include these experiments in the 
present study because coupling to these pathways is not a reliable read‐
out in an overexpression system and is highly variable between cell lines.
It is possible that other pathways that have not been tested in 
the present study could be affected, such as other posttranslational 
modifications (eg phosphorylation, palmitoylation, etc), receptor 
dimerisation or interaction with other membrane proteins and/or 
channels (eg Kir7.1). MC4R has four glycosylation sites but the func‐
tion of this receptor modification is still unclear. One of the variants 
tested in the present study, V50M, did exhibit a defect in glycosyla‐
tion, reduced responsiveness to α‐ and β‐MSH, and reduced the 
ability to couple to β‐arrestin, although it is unclear whether the 
glycosylation defect contributes to the altered signalling properties. 
Granell et al47 suggest that glycosylation status may not affect the 
function of the receptor.
In conclusion, through careful analysis of pharmacological prop‐
erties, we demonstrate that five of seven class V receptors tested 
have marked functional defects detectable in a simple transfection 
cell system. It is possible that some mutations (eg, the D37V or 
R305S mutations for which we found no significant phenotypes) are 
not causally linked to obesity, have defects that are only detectable 
in a neuronal cell milieu or are defective in yet unknown pharma‐
cological properties of the receptor. A second conclusion from the 
present study is that a majority of class V MC4R mutations associ‐
ated with obesity exhibit either decreased or increased β‐arrestin 
recruitment. This finding suggests that MC4R must couple normally 
to β‐arrestin for the normal regulation of energy homeostasis, and 
that biased ligands, differentiating β‐arrestin from Gsα signalling, 
should be developed and tested to determine the physiological con‐
sequences of β‐arrestin recruitment to the MC4R.
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